| Methods |
Five‐week randomised double‐blind study |
| Participants |
Outpatients with diagnosis of neurotic or reaction depressive disorder on the ICD, with a score of at least 17 on the Hamilton Rating Scale for Depression (HDRS).
Age range: 18‐65 years
Exclusion criteria: suicidality, severe organic disease, diabetes mellitus, glaucoma, hyperthyroidism, pregnancy, hypersensitivity to drug, abnormal liver values, organic psychosis, schizophrenia, psychopathy, addiction to alcohol or drugs, seizures. |
| Interventions |
Fluoxetine: 20 participants
Nomifensine: 20 participants
Fluoxetine dose: 40 mg/day
Nomifensine dose: 150 mg/day
Chloral hydrate or benzodiazepines for sleep were allowed |
| Outcomes |
HDRS, Clinical Global Impression (CGI), Symptom Check List of Taneri, Patient Global Impression (PGI), Zung Depression Scale (SDS) |
| Notes |
Funding: unclear |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Randomised, no further information |
| Allocation concealment (selection bias) |
Unclear risk |
No information provided |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Scores reported without denominators. Reasons and number of dropouts reported, but not included in the analysis |
| Selective reporting (reporting bias) |
Unclear risk |
End point mean scores and standard deviations reported. Only most common side effects reported |
| Other bias |
Unclear risk |
Funding: unclear |
